An overview of the ‘Health Impact Fund’ model for accessible medicines
A few quick facts before I jump into my post. US, EU and Japan together account for roughly 90% of the revenues received by pharmaceutical firms, and thus by far, are their largest money generators. Developed countries comprise of 16-20% of the global population Neglected diseases (or Type III diseases) receive about 2-3% of the global pharmaceutical R&D Even India, the ‘pharmacy of the developing world’, only 10% of R&D funding of the top 12 leading Indian pharma companies focus […]
An overview of the ‘Health Impact Fund’ model for accessible medicines Read More »

